| Tipoffs for Bangor, Maine (New England) Newsletter for Sunday February 22, 2026 ( 1 items ) |
|
Calquence Plus Venetoclax Approved in the US as First All-Oral, Fixed-Duration Combination for Patients With Chronic Lymphocytic Leukemia in the 1st-Line Setting
WILMINGTON, Delaware, Feb. 21 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
CALQUENCE(R) plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting
CALQUENCE plus venetoclax demonstrated statistically significant and clinically
meaningful improvement in progression-free survival vs. chemoimmunotherapy, with
77% of patients progression free at three years in AM
more
|
Sign up to Receive this newsletter every day via email.